Who Shall and Shall Not Have a Place in the World?
By Lily Hu,
Los Angeles Review of Books
| 02. 13. 2025
IN MAY 1921, the organizers of the Second International Congress of Eugenics assured the public that its conference, to be held later that year in September, would be taking a measured approach to “the topic of human racial differences.” All sides of the matter would be soberly considered; no conclusions would be reached in a hurry. The public could feel secure that, as the statement brightly declared, “certain prejudices directed toward existing races will be removed when allowance is made for the influence of their social and educational environment, and their fundamentally sound and strong racial characteristics are brought to light. On the other hand,” the announcement more somberly continued, “limits to development of certain races and the inalterability through education and environment of the fundamental characteristics of certain stocks will be considered.”
By the time the first meeting of the congress rolled around, a scant five months later, the science seemed to have been settled—and it apparently gave reason for considerable alarm. In his welcome address, Henry Fairfield Osborn, president of the American Museum of Natural History and soon-to-be...
Related Articles
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Carolyn Riley Chapman and Nirvan Bhatia, Hastings Bioethics Forum | 03.12.2026
Last year, researchers saved an infant named KJ from a life-threatening rare metabolic disorder using a customized gene editing therapy. This was the first time that an individualized gene therapy was used to treat a human patient, and it has...
By Alexandra Marquez, NBC News | 03.13.2026
“Donald Trump” by Gage Skidmore is licensed under CC BY-SA 2.0
President Donald Trump on Thursday blamed “the genetics” of assailants in a string of recent attacks across the country. He made the comments after attacks at a...